Compare GSK plc (GSK) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs MGM Resorts International — how do they compare? GSK plc trades at $52.6 (market cap $101.34B), while MGM Resorts International trades at $46.63 (market cap $11.98B). The key difference: GSK plc is far larger — about 8.5× MGM Resorts International's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | MGM | |
|---|---|---|
Market Cap | $101.34B | $11.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $50.69 |
52-Week Low | $36.20 | $30.72 |
Enterprise Value | $121.95B | $41.03B |
Dividend Yield | 3.49% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
MGM Resorts International (MGM) trades at $46.73, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $48.93. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 2026 missing slightly. The company maintains stable revenue around $17.5 billion but faces declining net profit margins, now at 1.03%. Acquisition interest from Barry Diller at $48.30 per share dominates recent news, potentially driving near-term volatility.
MGM offers moderate upside to the consensus target, supported by takeover speculation and solid cash flow, but high P/E of 64.16 and weak profitability metrics pose valuation risks. Investors should weigh acquisition prospects against fundamental challenges like debt levels and margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
